Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

February 7, 2020

Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st Patient

News

GlycoMimetics announced that the first patient with advanced breast cancer has been dosed in a Phase 1b clinical trial investigating the ability of its small molecule inhibitor, GMI-1359, to stop ... Read more

February 6, 2020February 12, 2020

Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial

News

A combination of the immune checkpoint inhibitor Keytruda (pembrolizumab) and the melanoma therapy Mektovi (binimetinib) is safe and well-tolerated by people with advanced triple negative breast cancer, preliminary findings ... Read more

January 24, 2020February 6, 2020

Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says

News

Zymeworks announced the start of a Phase 2 trial examining its experimental cancer treatment ZW25, in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and the hormone therapy Faslodex (fulvestrant), ... Read more

Pin It on Pinterest